The Patent Finder
US

Variant Form of Urate Oxidase and Use Thereof

US 7,964,381 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Apr 11, 2026 · High confidence

Filed Sep 10, 2010 as application 12/879,084 · Granted Jun 21, 2011
Base term, 20 years from filing
Today
20 years from filing
Term ended Apr 11, 2026
2006 2026
Clock starts
Apr 11, 2006
Term ended
Apr 11, 2026
Granted
Jun 21, 2011
base term after the term ends fee events Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
22
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Apr 11, 2006, when application PCT/US2006/013502, the earliest non-provisional in its chain, was filed (this one was filed Sep 10, 2010)Apr 11, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderApr 11, 2026High confidence

Partial family

Application PCT/US2006/013502PCT application
no patent term
no patent term
Application PCT/US2006/013660PCT application
no patent term
no patent term
US 8,148,123In force
Sep 2027
Sep 2027
Application 11/899,688Abandoned
not computed
not computed
US 7,811,800Term ended
Apr 2026
Apr 2026
US 8,188,224Term ended
Apr 2026
Apr 2026
US 7,964,381this patent
Apr 2026
Apr 2026
US 8,034,594Term ended
Apr 2026
Apr 2026
8 of 22 applications in this family shown, earliest filings first. Partial: 2 of the 22 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jun 12, 2012
Reel 28363, frame 40
Savient Pharmaceuticals, Inc.Morgan Stanley Senior Funding Inc.Security Agreement
Jul 23, 2013
Reel 30936, frame 72
Savient Pharmaceuticals, Inc.U.S. National Bank Association, as Collateral AgentCorrective Assignment to Correct the Receiving Party Previously Recorded on Reel 028363 Frame 0040. Assignor(S) Hereby Confirms the Security Agreement.
Feb 21, 2014
Reel 32319, frame 77
Crealta Pharmaceuticals LLCJefferies Finance LLC, as Collateral AgentSecurity Agreement
Mar 4, 2014
Reel 32384, frame 285
Crealta Pharmaceuticals LLCFifth Street Finance Corp., as Collateral AgentSecurity Agreement
Apr 15, 2014
Reel 32675, frame 936
Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, LLCCrealta Pharmaceuticals LLCAssignment of Assignor's Interest
Jan 13, 2016
Reel 37483, frame 49
Fifth Street Finance Corp., as Collateral AgentCrealta Pharmaceuticals LLCRelease of Security Interest
Jan 13, 2016
Reel 37483, frame 148
Jefferies Finance LLC, as Collateral AgentCrealta Pharmaceuticals LLCRelease of Security Interest
Sep 16, 2016
Reel 40059, frame 7
Horizon Pharma Rheumatology LLC (Formerly Known as Crealta Pharmaceuticals LLC)Citibank, N.A., as Collateral AgentPatent Security Agreement
Nov 18, 2016
Reel 40648, frame 361
Crealta Pharmaceuticals LLCHorizon Pharma USA Rheumatology LLCChange of Name
Nov 18, 2016
Reel 40648, frame 367
Horizon Pharma USA Rheumatology LLCHorizon Pharma Rheumatology LLCChange of Name
Oct 31, 2022
Reel 61805, frame 76
Horizon Pharma Rheumatology LLCHorizon Therapeutics USA, Inc.Assignment of Assignor's Interest
Dec 1, 2022
Reel 62073, frame 930
Horizon Pharma Rheumatology LLCHorizon Therapeutics USA, Inc.Corrective Assignment to Correct the Name of the Assignee Previously Recorded on Reel 061805 Frame 0076. Assignor(S) Hereby Confirms the Assignment.
Dec 22, 2022
Reel 62191, frame 611
Hartman, Jacob; Mendelovitz, SimonaSavient Pharmaceuticals, Inc.Assignment of Assignor's Interest
Jun 16, 2023
Reel 64009, frame 261
Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, Inc.Crealta Pharmaceuticals LLCCorrective Assignment to Correct the Seller's Name and Execution Date Previously Recorded on Reel 032675 Frame 0936. Assignor(S) Hereby Confirms the Seller's Name Should Read Savient Pharma Holdings, Inc. and the Execution Date for Both Parties Should Read 01/09/2014.
Oct 6, 2023
Reel 65178, frame 965
Citibank, N.a.Horizon Therapeutics USA, Inc.Release of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited